3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 3
2
Phase 1
1
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Dermatologic
4
Genitourinary
3
Thoracic
2
Sarcoma
2
Head & Neck
2
Gastrointestinal
2
Breast
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
81
Nivolumab
55
Ipilimumab
44
Cyclophosphamide
38
aldesleukin
26
Interleukin-2
25
fludarabine
17
Temozolomide
17
fludarabine phosphate
16
trametinib
11
dabrafenib
11
Radiotherapy
11
Biopsy
11
avelumab
10
Paclitaxel
9
spartalizumab
8
cemiplimab
8
Dacarbazine
8
Cisplatin
8
Bevacizumab
8
sargramostim
7
binimetinib
7
Fluorouracil
7
poly ICLC
6
lenvatinib
6
epacadostat
6
atezolizumab
6
Magnetic Resonance Spectroscopy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 1/2
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT03548467
2023-04-21
DIRECT-01
Nykode Therapeutics ASA
Phase 1/2
Completed
41 enrolled
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts